個人介紹:
1987-1994年在蘭州大學生物系學習,分獲學士及碩士學位,1997年于北京大學獲博士學位,1999年-2006年分别在美國克利夫蘭醫學中心及Scripps研究所從事博士後研究,現為北京大學特聘教授、北京大學長聘教授、北大-清華生命科學聯合中心高級研究員,國家“973計劃”項目首席科學家。
從事感染-免疫-腫瘤及其細胞信号轉導研究,近年來以通訊作者在Cell、Immunity(4篇)、Nature Immunology、Nature Cell Biology、Cell Research(3篇)、CMI(2篇)、Molecular Cell 和 PNAS(2篇)等期刊上發表多篇論文。曾獲“國家傑出青年科學基金”和 “談家桢生命科學創新獎”,2014年獲全國百篇優秀博士學位論文指導老師獎。
作為項目負責人主持了國家自然科學基金委的傑出青年基金、重點項目、重大研究計劃及科技部“973”項目。
教育經曆:
1994 - 1998, 理學博士, 細胞生物學, 北京大學
1991 - 1994, 理學碩士, 細胞生物學, 蘭州大學
1987 - 1991, 理學學士, 細胞生物學, 蘭州大學
工作經曆:
2012-現在,高級研究員,北京大學-清華大學生命科學聯合中心
2011-現在,教育部特聘教授
2011-2012,研究員,北京大學-清華大學生命科學聯合中心
2006-2011, “百人計劃”研究員, beat365官方网站
2003-2006, Research associate (博士後), The Scripps Research Institute, La Jolla, CA, USA
1999-2003, Research associate (博士後), The Lerner Research Institute, CCF, Cleveland, Ohio, USA
1997-1999, 博士後, beat365官方网站 社會服務工作:
1. 2010-至今, 國家自然科學基金委專家組成員, 國家自然科學基金委
2. 2010-2017, 國家自然科學基金委重大研究計劃專家組成員, 國家自然科學基金委
榮譽獎勵:
全國優秀博士學位論文指導教師,2014年
談家桢生命科學創新獎,2013年
教育部特聘教授,2011年
國家傑出青年科學基金,2010年
教育部“新世紀優秀人才”,2007年
學術任職:
1)中國免疫學會
2)中國細胞生物學學會
3)中國生化與分子生物學會評審任職:
1. 2010-至今, 國家自然科學基金委專家組成員, 國家自然科學基金委
2. 2010-2017, 國家自然科學基金委重大研究計劃專家組成員, 國家自然科學基金委
書籍編撰:
特邀綜述
1. Fang R. Jiang Q. Yu X. Zhao Z. and Jiang Z*. 2022, Recent advances in the activation and regulation of the cGAS-STING pathway. Advances in Immunology 156: 56-102.
2. Yu X. Zhao Z. and Jiang Z*. 2022, Recent progress on the activation of the cGAS–STING pathway and its regulation by biomolecular condensation. J. Mol. Cell Biol. 14(6), mjac042.
3. Wang C. Zhang R. Wei X. Lv M. and Jiang Z*. 2020, Metalloimmunology: The metal ion-controlled immunity. Advances in Immunology (ed. Dong C. and Jiang Z.) 145: 188-241.
4. Chen H, Ning X, Jiang Z*. 2017, Caspases control antiviral innate immunity. Cellular & Molecular Immunology 14: 736-747.
5. Gao J, Tao J, Liang W, Jiang Z*. 2016, Cyclic (di)nucleotides: the common language shared by Microbe and Host. Current Opinion in Microbiology 30: 79–87.
6. Tao J, Zhou X, Jiang Z*. 2016, cGAS-cGAMP-STING: The three musketeers of cytosolic DNA sensing and signaling. IUBMB Life 68: 858-870.
7. Chen H. and Jiang Z*. 2013, The essential adaptors of innate immune signaling. Protein & Cell 4: 27–39.
8. Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X and Hoebe K, 2006, Genetic Analysis of Host Resistance: Toll-like Receptor Signaling and Immunity at Large. Annual Review of Immunology 24: 353-389.
9. Hoebe K. Jiang Z, George P, Tabeta K, Janssen E, Du X, and Beutler B. 2006, TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy. Current Pharmaceutical Design 12: 4123-4134.
10. Hoebe K, Jiang Z, Tabeta K, Du X, Georgel P, Crozat K, Beutler B. 2006, Genetic analysis of innate immunity. Adv Immunol. 91: 175-226.
11. Beutler B, Georgel P, Rutschmann S, Jiang Z, Croker B, Crozat K. 2005, Genetic analysis of innate resistance to mouse cytomegalovirus (MCMV). Brief Funct Genomic Proteomic 4: 203-213.執教課程:
細胞生物學(本科生)
天然免疫(本科生)
免疫學進展(研究生)
細胞生物學進展(研究生) 研究領域:“感染-免疫-腫瘤”及其相關的細胞信号轉導
蔣争凡實驗室利用多種技術:大規模、高通量克隆表達及功能篩選、全基因組CRISPR/Cas9功能篩選和蛋白質分離-肽譜技術,對調控感染-免疫-腫瘤的相關蛋白進行大規模、高通量篩選、克隆及功能研究,尋找并發現新基因及已知基因在免疫中的新功能;利用免疫學、細胞生物學、分子生物學、生物化學、遺傳學、結構生物學等技術來研究這些基因的功能及作用機制,深入而系統地研究感染-免疫-腫瘤的分子機制,為相關疾病的預防和治療提供理論依據。
關鍵科學問題:
1)感染-免疫活化及調控的分子機制;
2)免疫與自身免疫病及腫瘤治療。
1. Fang R, Jiang Q, Jia X, and Jiang Z*. 2023, ARMH3-mediated recruitment of PI4KB directs Golgi-to-endosome trafficking and activation of the antiviral effector STING. Immunity 56: 500-515.
2. Fang R, Jiang Q, Guan Y, Gao P, Zhang R, Zhao Z, and Jiang Z*. 2021, Golgi-synthesized sulfated glycosaminoglycans mediate polymerization and activation of the cGAMP sensor STING. Immunity, 54: 962–975.
3. Yu X, Zhang L, Shen J, Zhai Y, Jiang Q, Yi M, Deng X, Ruan Z, Fang R, Chen Z, Ning X, Jiang Z*. 2021, The STING Phase-separator Suppresses Innate Immune Signaling. Nature Cell Biology, 23: 330-340.
4. Zhu L, Xi L, Wang C, Li C, Li M, Liu Q, Wang X, Yang W, Pan D, Hu L, Yang Y, Lu Z, Wang Y, Zhou D*, Jiang Z*, Shen X*. 2021, T6SS translocates a micropeptide to suppress STING-mediated innate immunity by sequestering manganese. Proc Natl Acad Sci USA. 118 (42): e2103526118.
5. Zhang R, Wang C, Guan Y, Wei X, Sha M, Jing M, Lv M, Guo W, Xu J, Wan Y, Jia X, Jiang Z*. 2021, Manganese salts function as potent adjuvants. Cellular & Molecular Immunology, 18: 1222–1234.
6. Yang J, Zhou X, Zhang R, Sun H, You F, Jiang Z*. 2021, Differences in IFNβ secretion upon Rab1 inactivation in cells exposed to distinct innate immune stimuli. Cellular & Molecular Immunology. 18: 1590–1592.
7. Lv M. Chen M, Zhang R, Zhang W, Wang C, Zhang Y, Wei X, Guan Y, Liu J, Feng K, Jing M, Wang X, Liu Y, Mei Q*, Han W*, Jiang Z*. 2020, Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Research, 30: 966–979.
8. Ning X, Wang Y, Jing M, Sha M, Lv M, Gao P, Zhang R, Huang X, Feng J, Jiang Z*. 2019, Apoptotic Caspases Suppress Type I Interferon Production via the Cleavage of cGAS, MAVS and IRF3. Molecular Cell, 74: 1-13.
9. Wang C, Guan Y, Lv M, Zhang R, Guo Z, Wei X, Du X, Yang J, Li T, Wan Y, Su X, Huang X, Jiang Z*. 2018, Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-stranded DNA and Is Required for the Host Defense against DNA Viruses. Immunity, 48: 675-687.
10. Wang Y, Ning X, Gao P, Wu S, Sha M, Lv M, Zhou X, Gao J, Fang R, Meng G, Su X, Jiang Z*. 2017, Inflammasome activation triggers caspases-mediated cleavage of cGAS to regulate responses to DNA virus infection. Immunity, 46: 393-404.
11. Chen H, Sun H, You F, Sun W, Zhou X, Chen L, Yang J, Wang Y, Tang H, Guan Y, Xia W, Gu J, Ishikawa H, Gutman D, Barber G, Qin Z, Jiang Z*. 2011, Activation of STAT6 by STING is Critical for Antiviral Innate Immunity. Cell, 147: 436-446.
12. You FP, Sun H, Zhou X, Sun WX, Liang SM, Zhai ZH & Jiang Z*. 2009, PCBP2 mediates degradation of the adaptor MAVS via the HECT ubiquitin ligase AIP4. Nature Immunology, 10: 1300-1308.
13. Sun W, Li Y, Chen L, Chen H, You F, Zhou X, Zhou Y, Zhai Z, Chen D, Jiang Z*. 2009, ERIS, an ER IFN stimulator, activates innate immune signaling through dimerization. PNAS, 106: 8653-8.
14. Gao J, Tao J, Liang W, Zhao M, Du X, Cui S, Duan H, Kan B, Su X, Jiang Z*. 2015, Identification and characterization of phosphodiesterase V-cGAPs that specifically degrade 3`3`-cyclic GMP-AMP. Cell Research, 25: 539-550.
15. Fang R, Jiang Q, Zhou X, Wang C, Guan Y, Tao J, Xi J, Feng J, Jiang Z*. 2017, MAVS activates TBK1 and IKKb through TRAFs in NEMO dependent and independent manner. PLoS Pathogens, 13(11): e1006720.
16. Fang R, Lin Y, Zhou X, Wang C, Guan Y, Tao J, Xi J, Feng J, Jiang Z*. 2017, NEMO-IKKβ Are Essential for IRF3 and NF-κB Activation in the cGAS-STING Pathway. J Immunology, 199: 3222-3233.
17. Tao J, Zhang X, Jin J, Du X, Lian T, Yang J, Zhou X, Jiang Z*, Su X*, 2017, Non-specific DNA binding by N-terminal domain promotes activation of human cyclic GMP-AMP synthase. J Immunology, 198: 3627-3636.
18. Gao J, Tao J, Liang W, Jiang Z*. 2016, Cyclic (di)nucleotides: the common language shared by Microbe and Host. Current Opinion in Microbiology, 30: 79–87.
19. Huang YH, Liu XY, Du XX, Jiang Z, Su XD*. 2012, The structural basis for the sensing and binding of cyclic di-GMP by STING. Nat Struct Mol Biol., 19: 728-30.
20. Zhou X, You F, Chen H, Jiang Z*. 2012, Poly(C)-binding protein 1 mediates house-keeping degradation of mitochondrial antiviral signaling (MAVS). Cell Research, 22: 717-727.
21. Xiao H, Qian W, Staschke K, Qian Y, Cui G, Deng L, Ehsani M, Wang X, Qian YW, Chen ZJ, Gilmour R, Jiang Z*, Li X*. 2008, Pellino 3b negatively regulates interleukin-1-induced TAK1-dependent NF kB activation. J Biol Chem., 283: 14654-64.
22. Jiang Z, Georgel P, Li C, Choe J, Crozat K, Rutschmann S, Du X, Bigby T, Mudd S, Sovath S, Wilson I A, Olson A, Beutler B. 2006, Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis. PNAS, 103: 10961-66.
23. Jiang Z, Georgel P, Du X, Shamel L, Sovath S, Mudd S, Huber M, Kalis C, Keck S, Galanos C, Freudenberg M, Beutler B. 2005, CD14 is required for MyD88-independent LPS signaling. Nature Immunology, 6: 565-70.
24. Jiang Z, Mak TW, Sen G, Li X. 2004, Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. PNAS, 101: 3533-8.
25. Jiang Z, Zamanian-Daryoush M, Nie H, Silva AM, Williams BR, Li X. 2003 Poly (I-C)-induced TLR3-mediated activation of NFkappa B and MAP kinase is through an IRAK-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J Biol Chem., 278: 16713-9.
26. Jiang Z, Johnson HJ, Nie H, Qin J, Bird TA, Li X. 2003, Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling through its interaction with the IRAK4-IRAK-TRAF6 complex. J Biol Chem., 278: 10952-6.
27. Jiang Z, Ninomiya-Tsuji J, Qian Y, Matsumoto K, Li X. 2002, Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol Cell Biol., 22: 7158-67.
28. Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X and Hoebe K, 2006, Genetic Analysis of Host Resistance: Toll-like Receptor Signaling and Immunity at Large. Annual Review of Immunology, 24: 353-89.
研究領域:“感染-免疫-腫瘤”及其相關的細胞信号轉導
識别細胞内DNA的cGAS-STING通路對抗感染和抗腫瘤的免疫監視及治療至關重要。蔣争凡實驗室是發現STING蛋白重要功能的三個實驗室之一(命名為ERIS,PNAS, 2009)及其二聚化(寡聚化)的重要作用,并對其進行了深入系統的研究:發現轉錄因子NFkB和STAT6對該通路介導的免疫反應非常重要(JI, 2017a;Cell, 2011);硫酸化糖胺聚糖是STING活化必需的第二類配體及其高爾基體轉運的原因(Immunity, 2021);ARMH3-PI4KB合成的PI4P驅動STING的内體轉運并維持活化(Immunity, 2023);STING通過形成“相分離器”調節天然免疫(Nature Cell Biology, 2021);Caspases負調控天然免疫反應,包括炎症小體活化的Caspases(Immunity, 2017;JI, 2017b)及凋亡活化的Caspases(Molecular Cell, 2019),避免過度免疫反應并保證細胞凋亡“免疫沉默”;錳離子對于機體抗感染重要(Immunity, 2018;PNAS, 2021),Mn2+是細胞内cGAS的第二個激活劑,以獨特方式激活cGAS(Cell Reports, 2020),以此為基礎發明了可激活細胞免疫、體液免疫和黏膜免疫的錳佐劑(CMI, 2021)及增強腫瘤免疫治療的“錳免療法”(Cell Research, 2020);發現3`3`-cGAMP特異性磷酸二酯酶(Cell Research, 2015)。此外,發現PCBPs-AIP4介導的蛋白質降解途徑負調控天然免疫關鍵分子MAVS降低或避免RNA病毒感染引發的過度反應(Nature Immunology, 2009; Cell Research, 2012)以及NEMO-IKKα/β對于RIG-I-MAVS通路中激活TBK1/IKKε至關重要(PLoS Pathogens, 2017)。
蔣争凡實驗室利用多種技術:大規模、高通量克隆表達及功能篩選、全基因組CRISPR/Cas9功能篩選和蛋白質分離-肽譜技術,對調控感染-免疫-腫瘤的相關蛋白進行大規模、高通量篩選、克隆及功能研究,尋找并發現該通路中的新基因及已知基因在天然免疫中的新功能;利用免疫學、細胞生物學、分子生物學、生物化學、遺傳學、結構生物學等技術來研究這些基因的功能及作用機制,深入而系統地研究感染-免疫-腫瘤的分子機制,為相關疾病的預防和治療提供理論依據。實驗室電話62767578